Current Report Filing (8-k)
July 28 2014 - 4:46PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
July 22, 2014
Date
of report (Date of earliest event reported)
SOLAZYME,
INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
| Delaware |
|
001-35189 |
|
33-1077078 |
| (State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification Number) |
|
|
| 225 Gateway Boulevard
South San Francisco, CA 94080 |
|
94080 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
(650) 780-4777
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2 below):
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01 Entry Into a Material Definitive Agreement.
On July 22, 2014, Solazyme, Inc. (the “Company”) entered into a lease agreement (the “Lease”) with Britannia Gateway
II Limited Partnership (the “Landlord”) to lease approximately 106,076 rentable square feet located at 225 Gateway Boulevard and 201 Gateway Boulevard, South San Francisco, California (collectively, the “Premises”). The Lease
will commence on February 5, 2015 and expire on January 31, 2018 (the “Term”). The Lease payments will be approximately $12.4 million over the Term, and the Company will also pay the Landlord for certain operating expenses.
The Company currently occupies the Premises under a sublease dated December 31, 2009, between the Company, as sublessee, and FibroGen,
Inc., as sublessor.
The above description is a summary of the material terms of the Lease, does not purport to be complete, and is
qualified in its entirety by reference to the agreement, which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The information set forth in Item 1.01 above is incorporated by reference into this Item 2.03.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SOLAZYME, INC. |
|
|
|
|
(Registrant) |
|
|
|
|
| Date: July 28, 2014 |
|
|
|
By: |
|
/s/ Tyler W. Painter |
|
|
|
|
|
|
Tyler W. Painter |
|
|
|
|
|
|
Chief Operating Officer and Chief
Financial Officer |